• About Us
    • About Isofol
    • Business Concept
    • Organisation
      • Management
    • Collaborators
    • History
      • Isofol founded
  • Clinical Studies
    • The AGENT study (Phase III)
    • 005-study (Phase I/IIa)
      • 005-study data
    • Additional studies
    • Summary clinical studies
    • Clinical development plan
  • arfolitixorin
    • About arfolitixorin
    • About colorectal cancer
      • Medical need & Marketing potential
      • Treatment of colorectal cancer
    • Treatment of other types of cancer
      • About Osteosarcoma
    • Statements about arfolitixorin
      • Merck & Cie
      • Skövde Sjukhus
    • Arfolitixorin animation
    • Scientific concept
    • Publications
    • Intellectual proporty rights
  • Investor Relations
    • Share information
    • Analysts
    • Company presentations
    • Financial Reports
    • Financial Calendar
    • Rights issue 2020
    • Initial public offering 2017
    • IR Contact and Certified Adviser
    • Share owners
  • Corporate Governance
    • Corporate Governance
      • Corporate Governance Reports
    • Articles of Association
    • General Meetings
    • Board
    • Work of the Board
    • Remuneration Committee
      • Remuneration
      • Incentive Programs
    • Audit Committee
    • Auditors
    • Nomination Committee
    • Management
  • News room
    • News & Press releases
    • Media coverage
    • Subscribe
  • Contact
    • Visit us
    • Career
    • Management
  • Swedish
Isofol Isofol
Isofol Isofol
  • About Us
    • About Isofol
    • Business Concept
    • Organisation
      • Management
    • Collaborators
    • History
      • Isofol founded
  • Clinical Studies
    • The AGENT study (Phase III)
    • 005-study (Phase I/IIa)
      • 005-study data
    • Additional studies
    • Summary clinical studies
    • Clinical development plan
  • arfolitixorin
    • About arfolitixorin
    • About colorectal cancer
      • Medical need & Marketing potential
      • Treatment of colorectal cancer
    • Treatment of other types of cancer
      • About Osteosarcoma
    • Statements about arfolitixorin
      • Merck & Cie
      • Skövde Sjukhus
    • Arfolitixorin animation
    • Scientific concept
    • Publications
    • Intellectual proporty rights
  • Investor Relations
    • Share information
    • Analysts
    • Company presentations
    • Financial Reports
    • Financial Calendar
    • Rights issue 2020
    • Initial public offering 2017
    • IR Contact and Certified Adviser
    • Share owners
  • Corporate Governance
    • Corporate Governance
      • Corporate Governance Reports
    • Articles of Association
    • General Meetings
    • Board
    • Work of the Board
    • Remuneration Committee
      • Remuneration
      • Incentive Programs
    • Audit Committee
    • Auditors
    • Nomination Committee
    • Management
  • News room
    • News & Press releases
    • Media coverage
    • Subscribe
  • Contact
    • Visit us
    • Career
    • Management
  • Swedish

Work of the Board

The main responsibility
of the board of directors

The main responsibility of the board of directors is to, on behalf of the shareholders, manage the company’s business and operations and be responsible for the company’s organisation. The chairman of the board leads the work of the board. Immediately following the AGM the board shall have founding meeting and during the year the board shall meet regularly but in addition whenever requested. At the founding meeting resolutions are taken on signing on behalf on company, adoption of written instructions for the CEO and for the financial reporting and the rules of procedure for the board. The meetings of the board of directors includes i.e., the company’s financial situation, the development of the operations and other current topics where the board shall have information. The board of directors have the supervision of the work of the CEO, i.e. follow up that the CEO executes the decisions taken by the board of directors. Further, the board of directors prepares and proposes principles for remuneration of the management of the company which principles are adopted by the AGM. The board of directors also prepares and proposes any incentive program before the AGM. The company’s auditor is present and reports at board meetings whenever necessary. The board of directors is qualified to take any resolution if more than half of the directors are present at the meeting. Currently Isofol’s board of directors consists of seven directors.

BOARD COMMITTEES

The board of directors has set up two committees, the audit committee and the remuneration committee. The board of directors has adopted rules of procedure for both committees.

Audit committee

The audit committee’s role is primarily to monitor the Company’s financial position, to monitor the effectiveness of the Company’s internal control, internal audit and risk management, to be informed about the audit of the annual report and consolidated financial statements, and to review and monitor the auditor’s impartiality and independence. The audit committee shall also assist the nomination committee in proposals for resolutions on the election and remuneration of the auditor. Read more >>

Remuneration committee

The remuneration committee’s role is primarily to prepare matters regarding remuneration and other terms of employment for the CEO and other members of senior management. The remuneration committee shall also monitor and evaluate ongoing and completed programmes for variable remuneration to the Company’s management and monitor and evaluate the implementation of the guidelines for remuneration to senior management adopted by the annual general meeting. Read more >>

 

  • Corporate Governance
    • Corporate Governance Reports
  • Articles of Association
  • General Meetings
  • Board
  • Work of the Board
  • Remuneration Committee
    • Remuneration
    • Incentive Programs
  • Audit Committee
  • Auditors
  • Nomination Committee
  • Management
About Isofol
Isofol Medical AB (publ) is a biotech company within the field of oncology developing arfolitixorin, primarily as a treatment for advanced colorectal cancer and as a rescue drug after high-dose methotrexate treatment in osteosarcoma (bone cancer).
Contact
Isofol Medical AB (publ)
Biotech Center, Arvid Wallgrens Backe 20
SE-413 46 Gothenburg
Sweden

Phone: +46 (0)31 7972280
E-mail: info@isofolmedical.com
Newsletter and Privacy Policy
Sign up here to receive information, press releases and news and agree to Isofol’s processing of your personal data according to the company’s Integrity.
Isofol´s Integrity Policy (general)
Isofol´s Integrity Policy (clinical studies)
©2019 Isofol Medical AB (publ) Biotech Center, Arvid Wallgrens Backe 20, SE-413 46 Gothenburg, Sweden.
Isofol´s Glossary
Isofol's website uses cookies to improve and customize your visit. By continuing you accept this.Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are as essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.